MedPath

A open label, randomized, controled trial to assess the usefulness of telmisartan in patients with type 2 diabetes, obesity, and NAFLD.

Not Applicable
Recruiting
Conditions
type 2 diabetes mellitus
Registration Number
JPRN-UMIN000002641
Lead Sponsor
MATSUYAMA SHIMIN HOSPITA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients whose fatty liver is difficult to evaluate. (A heavy drinker, other liver diseases, etc.) 2) Patients requiring hospitalization to attain glycemic control. 3) Patients judged inadequate to participate in this study by their physician.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Content of visceral fat and fatty liver
Secondary Outcome Measures
NameTimeMethod
HbA1c, fasting glucose, fasting CPR, ABI/PWV, body weight, blood pressure
© Copyright 2025. All Rights Reserved by MedPath